JANX011 Shows B Cell Depletion in Healthy Volunteers

Janux reported first human pharmacology for JANX011, a CD19 T-cell engager that recruits TRBV6-positive rather than all CD3-positive T cells. At 3 mg subcutaneously, three of five healthy volunteers had more than 90% peripheral…




